The group’s principle activities include discovering, developing and commercializing mall-molecule medicines for the treatment of hepatitis and cancer. The group’s clinical development programs include ANA975, an oral prodrug of the Toll-like receptor-7 (TLR-7) agonist isatoribine, for the treatment of hepatitis C virus (HCV) and hepatitis B virus (HBV). The group operates from United States.
